Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Federico Rojo

Hospital Universitario Fundación Jiménez Díaz

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

30%

Biostatistics

30%

Cancer Biology

70%

Oncology

40%

Fibroblast Biology

30%

Biomarker Research

30%

Tumor Suppressor

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer

Article Link

Year:

2025

Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.

Article Link

Year:

2021

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.

Article Link

Year:

2021

A Novel NFIX-STAT6 Gene Fusion in Solitary Fibrous Tumor: A Case Report.

Article Link

Year:

2021

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.

Article Link

Year:

2021

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.

Article Link

Year:

2021

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.

Article Link

Year:

2021

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing.

Article Link

Year:

2021

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer.

Article Link

Year:

2021

Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).

Article Link

Year:

2021

Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients.

Article Link

Year:

2021

Collaborators3

Enrique de Alava

Professor

Universidad de Sevilla

SPAIN

Javier Martinez-Useros

SPAIN

Esther Conde

Universidad Complutense de Madrid

SPAIN

How do I reach out?

Meet Kite AI

Federico Rojo

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles11

Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer

Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.

A Novel <i>NFIX-STAT6</i> Gene Fusion in Solitary Fibrous Tumor: A Case Report.

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.

Molecular diagnosis in non-small-cell lung cancer: expert opinion on <i>ALK</i> and <i>ROS1</i> testing.

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer.

Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).

Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients.

Collaborators3

Enrique de Alava

Javier Martinez-Useros

Esther Conde

How do I reach out?